Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply: Co-occurrence of MYC amplification and TP53 mutations in human cancer

Nature Genetics volume 48, pages 106–108 (2016)Cite this article

Subjects

Leiserson et al . reply:

We are pleased to see the careful investigation by Ulz, Heitzer and Speicher of the MYC oncogene in The Cancer Genome Atlas (TCGA) pan-cancer data. The role of MYC as an oncogene is well known and widely documented1,2. Furthermore, MYC amplification is one of the most frequent copy number aberrations in TCGA pan-cancer data3,4. Yet, as Ulz, Heitzer and Speicher note, MYC did not appear in the pan-cancer networks from our recent study5.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Network and mutation properties of 338 highly mutated genes.

References

  1. Meyer, N. & Penn, L.Z. Nat. Rev. Cancer 8, 976–990 (2008).

    Article  CAS  Google Scholar 

  2. Dang, C.V. Cell 149, 22–35 (2012).

    Article  CAS  Google Scholar 

  3. Zack, T.I. et al. Nat. Genet. 45, 1134–1140 (2013).

    Article  CAS  Google Scholar 

  4. Ciriello, G. et al. Nat. Genet. 45, 1127–1133 (2013).

    Article  CAS  Google Scholar 

  5. Leiserson, M.D.M. et al. Nat. Genet. 47, 106–114 (2015).

    Article  CAS  Google Scholar 

  6. Cancer Genome Atlas Network. Nature 490, 61–70 (2012).

  7. Lawrence, M.S. et al. Nature 499, 214–218 (2013).

    Article  CAS  Google Scholar 

  8. Dees, N.D. et al. Genome Res. 22, 1589–1598 (2012).

    Article  CAS  Google Scholar 

  9. Ding, L., Wendl, M.C., McMichael, J.F. & Raphael, B.J. Nat. Rev. Genet. 15, 556–570 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Computer Science, Brown University, Providence, Rhode Island, USA

    Mark D M Leiserson, Fabio Vandin, Hsin-Ta Wu & Benjamin J Raphael

  2. Center for Computational Molecular Biology, Brown University, Providence, Rhode Island, USA

    Mark D M Leiserson, Fabio Vandin, Hsin-Ta Wu & Benjamin J Raphael

  3. Department of Information Engineering, University of Padova, Padova, Italy

    Fabio Vandin

Authors
  1. Mark D M Leiserson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Vandin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hsin-Ta Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benjamin J Raphael
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin J Raphael.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leiserson, M., Vandin, F., Wu, HT. et al. Reply: Co-occurrence of MYC amplification and TP53 mutations in human cancer. Nat Genet 48, 106–108 (2016). https://doi.org/10.1038/ng.3491

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.3491

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer